SCHEMBL802280

SCHEMBL802280

Cc1cc(Nc2n[nH]c3ccccc23)nc(-c2ccccc2C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FADS1 O60427 3/20 0.42
GSK3A P49840 2/20 0.42
GSK3B P49841 2/20 0.42
TRPA1 O75762 1/20 0.42
GRM4 Q14833 4/20 0.41
ADRA2A P08913 2/20 0.40
PIK3CD O00329 1/20 0.39
PIK3CA P42336 1/20 0.39
PIK3CB P42338 1/20 0.39
MTOR P42345 1/20 0.39
PIK3CG P48736 1/20 0.39
AURKA O14965 2/20 0.39
AURKB Q96GD4 1/20 0.39
EGFR P00533 2/20 0.37
RAB9A P51151 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
NPC1 O15118 2/20 0.36
HPGD P15428 2/20 0.36
ALOX15 P16050 2/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL802346 0.88 GSK3B (0.55) FADS1GSK3AGSK3BTRPA1GRM4
SCHEMBL802675 0.88 GSK3A (0.51) FADS1GSK3AGSK3BAURKAAURKB
SCHEMBL802348 0.87 FADS1 (0.40) FADS1GSK3AGSK3BTRPA1GRM4
SCHEMBL12619825 0.85 ACP1 (0.41) FADS1GSK3AGSK3BTRPA1GRM4
SCHEMBL801684 0.84 EGFR (0.39) FADS1GSK3AGSK3BTRPA1GRM4
SCHEMBL802062 0.83 CYP1A2 (0.43) ADRA2AAURKAEGFRALDH1A1TSHR
SCHEMBL801650 0.82 FADS1 (0.41) FADS1TRPA1GRM4ADRA2APIK3CD
SCHEMBL802674 0.81 GSK3A (0.44) FADS1GSK3AGSK3BTRPA1GRM4
SCHEMBL802685 0.81 GRM4 (0.39) FADS1GSK3AGSK3BTRPA1GRM4
SCHEMBL802326 0.81 FADS1 (0.48) FADS1TRPA1GRM4ADRA2APIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633210-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 US disclosed
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, GSK3A, CDK19 FADS1 3442/4885GSK3A 2/4885GSK3B 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.